Instil Bio (TIL) Stock Price, News & Analysis

Company Overview

Instil Bio, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for the treatment of cancer. The company’s research centers on tumor-infiltrating lymphocytes (TILs), immune cells that naturally recognize and attack cancer cells. Instil Bio aims to improve TIL therapies through its cell-engineering and manufacturing capabilities, with the goal of producing treatments that are more potent, consistent and scalable.

The company’s pipeline has included genetically modified TIL candidates designed to enhance anti-tumor activity and address limitations associated with conventional TIL therapies. Its programs have been investigated for the treatment of solid tumors, an area in which developing effective cellular immunotherapies remains challenging.

Instil Bio was established in 2018 and has operated as a U.S.-based biotechnology company, with research and development activities supported by cell-therapy expertise in the United States and the United Kingdom. Its programs remain in clinical development, and the company’s work is focused primarily on advancing engineered TIL therapies toward potential commercialization.

Key Stats

• Today's Range: $7.08 to $7.21
• 50-Day Range: $7.09 to $7.86
• 52-Week Range: $5.67 to $21.98
• Volume: 27,516 shs
• Average Volume: 10,408 shs
• Market Capitalization: $48.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Reduce

Instil Bio Stock Analysis - MarketRank™

Instil Bio scored higher than 14% of companies evaluated by MarketBeat, and ranked 840th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Instil Bio has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Instil Bio is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Instil Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Instil Bio is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Instil Bio is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Instil Bio has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.36% of the float of Instil Bio has been sold short.

Short Interest Ratio / Days to Cover

Instil Bio has a short interest ratio ("days to cover") of 22.89, which indicates bearish sentiment.

Change versus previous month

Short interest in Instil Bio has recently decreased by 11.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Instil Bio does not currently pay a dividend.

Dividend Growth

Instil Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Instil Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Instil Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

47.00% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TIL
• CIK: 1625584
• Web: www.tillcap.com
• Phone: 972-499-3350
• Fax: N/A
• Employees: 410
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Instil Bio: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: -1.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$71.37 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.78%
• Return on Assets: -14.89%

Debt

• Debt-to-Equity Ratio: 0.79
• Current Ratio: 21.67
• Quick Ratio: 21.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.79 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 6,782,000
• Free Float: 3,594,000
• Market Cap: $48.08 million
• Optionable: No Data
• Beta: 1.91